HUMIRA (Abbvie Pty Ltd)
Product name
HUMIRA
Sponsor
Date registered
Evaluation commenced
Decision date
Approval time
169 (255 working days)
Active ingredients
Adalimumab
Registration type
EOI
Indication
Paediatric Uveitis
Humira is indicated for the treatment of chronic non-infectious anterior uveitis in paediatric patients 2 years of age and older who have had an inadequate response to or are intolerant to conventional therapy, or in whom conventional therapy is inappropriate.